Expedited Review Processes

Most companies take days to make product decisions. We do it in 10 minutes. At Duolingo, Product Review (PR) is the heartbeat of our product development – and probably our most important meeting (of course, I’m biased!). When I joined Duolingo almost ten years ago, product decisions happened casually, often in informal chats at our desks. It worked for a while, but as we grew, it became a mess – key stakeholders were left out, and sometimes it wasn't clear if decisions were final or just thoughts. Over the years, we’ve transformed Product Review into a structured, efficient process that helps us move fast while also maintaining the bar for quality in our product. Here's how our Product Review works: -Each proposal gets exactly 10 minutes (down from 20, initially). The rationale for this length is because we want people to have clear, concise, and strong convictions. This saves time, but it also ensures what they are presenting is something they believe in. Luis von Ahn, our CEO, attends every single meeting. -We have three review formats based on the development stage: one-pager reviews for initial ideas, 1.5-pager reviews for concepts with rough designs, and spec reviews for fully fleshed-out features. -Reviewers are clearly marked and give feedback in a specific order, creating structure. (We also periodically switch up who the key reviewers are.) The meetings are open to anyone in the company. Beyond transparency, this serves as a training ground for developing product sense. -After each two-hour block of reviews, we hold a 15-minute debrief to evaluate decisions and continuously improve the process itself. The result? Fast decisions – but also enough structure to maintain our standard of quality across the app. Here’s a 1.5-pager from Emilia Cabrera, a product manager on our team, about an improvement for our streak session end screen. #productmanagement

Meta wanted to speed up code reviews without sacrificing quality. Here’s how they did it: 1. They identified the problem using developer experience surveys, finding frustration with slow code reviews. The team targeted the slowest 25% of reviews (p75 Time in Review). 2. Enter NudgeBot—an internal tool they developed that prompts reviewers to act on "stale" diffs untouched for 24 hours. It’s smart too, considering relationships and past interactions to decide who to nudge. 3. The results? In a 28-day experiment with 31k developers, NudgeBot cut Time in Review by 6.8%, reduced diffs taking over 3 days to close by 11.89%, and improved time to first action by 9.9%. Importantly, there were no negative side effects, such as rushed reviews. Meta’s systematic approach—using surveys to pinpoint issues, linking data to solutions, and rigorously testing—offers a solid blueprint for Developer Productivity teams: https://lnkd.in/dXzQbPGH

“Change is hard because people overestimate the value of what they have and underestimate the value of what they may gain giving that up.” People continue to ask, “why is South Korea is so much more efficient at advancing new nuclear technologies? Let’s focus on just one of the root causes… regulatory oversight processes. 👉 KINS serves as the primary regulatory body for nuclear safety in S. Korea, which centralizes the licensing process allowing for more cohesive decision-making and communication. The NRC's structure involves multiple layers of approval and oversight, which leads to longer review times and more complicated interactions among various agencies and stakeholders. 👉 KINS has established standardized guidelines and checklists for licensing applications, allowing for a more predictable and efficient review process. This includes pre-application consultations that help applicants understand requirements early in the process. In contrast, the NRC relies on a more case-by-case basis for its reviews, which results in variability of timelines and requirements, often depending on the specifics of each application. 👉 KINS has adopted advanced simulation and modeling technologies to assess safety and performance, which expedites evaluations and reduce the need for extensive physical testing. While the NRC is also exploring advanced technologies, the incorporation of these tools has been much slower, and traditional methods still dominate the review process (we are looking at you, analog systems in control rooms!). 👉 KINS has made efforts to reduce the volume of required documentation for licensing applications, focusing on ESSENTIAL safety and performance criteria. The NRC requires extensive documentation, which prolongs the review process. The emphasis on comprehensive safety assessments often result in a significant amount of paperwork regardless of its relevance to safety and security. 👉 KINS engages with stakeholders early in the process and has established forums for public input, which helps to address concerns before formal applications are submitted. While the NRC does allow for public comments, the complexities of the review process often lead to public engagement occurring after substantial decisions have been made, often times resulting in contentious debates that are resource intensive for the NRC and their licensees. 👉 KINS completes licensing reviews within a few years. The NRC's licensing process takes a decade or more, especially for new reactor designs or significant modifications to existing plants. 👉 KINS is very proactive in developing regulatory frameworks for new technologies and advanced reactor designs, allowing for more agile responses to innovations in the industry. The NRC has been much slower to adapt its regulatory framework to accommodate new technologies, which is hindering the development and deployment of advanced reactors at a reasonable cost. A gentle reminder: aim for excellence!

In a major step towards simplifying environmental compliance, the Ministry of Environment, Forest, and Climate Change (MoEF&CC) has issued a new Office Memorandum (OM) that streamlines how industries obtain environmental clearances (EC) and consents to establish (CTE). Here's what this means for industries, regulatory bodies, and stakeholders: The government has introduced G.S.R. 702(E) and G.S.R. 703(E) notifications, which exempt certain industries/projects from obtaining a separate Consent to Establish (CTE) under the Water Act (1974) and Air Act (1981). Instead, the conditions for CTE will now be integrated into the Environmental Clearance (EC) process. This simplification is part of an effort to reduce duplication and make processes more efficient for businesses while ensuring environmental safeguards remain intact. Here’s a breakdown of the new procedure: 1. Streamlined Role of SPCBs/PCCs The State Pollution Control Boards (SPCBs) and Pollution Control Committees (PCCs) will play a key role in the EC process: Projects Requiring ToR (Terms of Reference): SPCBs/PCCs will receive the ToR and provide comments on the project site, feasibility, and environmental safeguards through the PARIVESH portal. Projects Without ToR (e.g., smaller projects or expansions): The EC proposal will be shared directly with SPCBs/PCCs for comments. 2. Timelines for Comments SPCBs/PCCs must respond promptly: 30 days for projects with ToR. 15 days for projects without ToR. If comments aren’t received within the timeframe, the project can proceed based on available data, ensuring no unnecessary delays. 3. Fee Payment Project proponents must pay the required fee within 7 days of receiving the demand from SPCBs/PCCs. Once the receipt is uploaded, comments will follow. 4. Simplified Review Process If SPCBs/PCCs fail to respond, their feedback will be treated as no objection, and decisions will proceed in the Environmental Appraisal Committee (EAC). For Projects Already Granted EC If a project received an EC after November 12, 2024, but hasn’t obtained a CTE: It must secure environmental safeguards from SPCBs/PCCs within 30 days of this OM. These safeguards will be added to the EC conditions. What’s Still Required? Even with this exemption, projects must: Obtain a Consent to Operate (CTO) from SPCBs/PCCs. Secure any other necessary permissions as per existing laws. What Does This Mean for Industries? This change is a win for industries that often faced delays due to overlapping processes. By integrating CTE conditions into EC approvals: Processes are faster and more efficient. Environmental compliance remains robust. This streamlined approach reflects India’s commitment to balancing economic development with environmental responsibility. Whether you’re an industry leader, consultant, or policymaker, these changes promise a smoother path toward sustainable growth.

🔬 The Life Cycle of an IRB Protocol: A Scientific Overview The life cycle of an Institutional Review Board (IRB) protocol reflects the structured oversight required to ensure that human subject research is ethical, scientifically valid, and compliant with regulatory standards. Each phase of the process plays a critical role in protecting participant rights and safeguarding data integrity. 1. Protocol Development Researchers begin by designing a scientifically sound study that minimizes risk and maximizes potential benefits. This includes developing the methodology, defining inclusion/exclusion criteria, establishing safety monitoring plans, and creating informed consent documents that clearly communicate study purpose, risks, and procedures. 2. Submission to the IRB A comprehensive submission package is prepared and uploaded to the IRB system. It typically includes the protocol, consent forms, recruitment materials, investigator brochures, data safety plans, and any tools used for data collection. Accuracy and completeness at this stage streamline later review cycles. 3. Administrative Pre-Review The IRB office performs a preliminary screening to ensure compliance with federal regulations (e.g., 45 CFR 46, 21 CFR 50/56), institutional policies, and submission requirements. Missing documents or inconsistencies are addressed before full review. 4. IRB Review (Exempt, Expedited, or Full Board) Depending on the level of risk, protocols undergo one of three types of review: Exempt: Minimal risk studies that fall under exempt categories. Expedited: Minimal risk studies reviewed by a designated IRB reviewer. Full Board: Studies involving more-than-minimal risk or vulnerable populations. Reviewers assess scientific validity, risk–benefit ratio, consent process, privacy protections, and investigator qualifications. 5. Investigator Response & Revisions Researchers address any IRB comments or modifications required for approval. This may involve clarifying procedures, enhancing participant protections, or revising study materials. 6. IRB Approval Once all concerns are resolved, the IRB issues formal approval. The study can begin only after documented approval is in place. Approval letters specify conditions, reporting requirements, and the approval period (typically 1 year). 7. Ongoing Oversight (Continuing Review & Amendments) Throughout the study, the IRB continuously monitors: **Continuing review reports “Every IRB protocol follows this complex journey—yet each one shapes the future of ethical research. Which stage do you find the most challenging or fascinating? Let’s discuss.” #IRB #EthicsInResearch #ClinicalResearch #ResearchCompliance #HumanSubjectsProtection #GCP #Regulations #ClinicalTrials #ResearchGovernance #Bioethics #ProtocolDevelopment #MedicalResearch #PharmaResearch #CRO #LifeSciences #RegulatoryAffairs

We recently ran an A/B analysis with a significant enterprise (500 developers) across 6 major repositories to see what happens when AI-driven code reviews (like Bito CRA) take the lead. The results? Pretty clear. 3,000 PRs. 4 billion tokens consumed. 49% faster code reviews. 1. Speed: PRs closed 49% faster with AI feedback compared to human-only reviews. In September, human reviews averaged 12.4 days to close. With AI? 8.1 days. By October, humans took 7.1 days. AI dropped that to just 3.6 days. 2. Immediate feedback: AI provides initial feedback in 4 minutes on average. Compare that to human-led reviews, where developers waited 1,414 minutes (~1 full day). 3. Feedback acceptance: Developers accepted 30% of Bito CRA’s suggestions in October. This is steadily increasing as teams build trust in AI feedback. 4. Consistency: Across 6 key repos, close times improved between 37% and 82%. Only one repo didn’t see significant improvement. And here’s the kicker: Bito CRA handled over 80% of the total feedback on PRs… this means reviewers were able to focus on strategic aspects of code review like design and architecture. And developers get feedback ASAP, address it, and move on to the next thing! We’re seeing developers get faster, reviews get cleaner, and teams get back their time. What would your team do with a 49% faster code review cycle? #developer #code #ai #codereview

🕒 “We’re running late — still waiting for feedback from different departments.” A line that pops up often during sustainability reporting. While consultants may help structure and draft the report, review delays often happen internally — especially in large organizations where the document passes through multiple hands: ESG, HR, Compliance, Legal, CSR, Finance, Communications… The result? A well-prepared report gets stuck in loops — delayed not because of content gaps, but because feedback isn’t coordinated. So how can internal teams streamline the review process and avoid bottlenecks? Here are certain solutions that can help: 🔹 1. Appoint a Central ESG Coordinator Designate a single point of contact internally who manages all inputs, sets timelines, and nudges departments with accountability. 🔹 2. Use a Shared Tracker or Platform Leverage shared project trackers , or other project management tools can help track which section is pending with whom — making status visible and reducing back-and-forth emails. 🔹 3. Set Review Windows — Not Open-Ended Deadlines Structure the review in 2-3 day windows for each department. Too much time = low priority. 🔹 4. Phase-wise Review Instead of Waiting for Full Draft Start parallel reviews: HR reviews HR sections, CSR team reviews their part — this reduces pressure at the final stage. 🔹 5. Make It Easy to Review Use ‘tracked changes’, comment-enabled PDFs, or even review-friendly summaries. The easier it is to give feedback, the faster it comes. 🔹 6. Align Expectations Early Kick-off the reporting cycle with all departments involved — align on structure, responsibilities, and timelines. Prevent surprises later. If you’re a large organization preparing your next ESG or BRSR report — these small changes can speed up the process without compromising quality. Have you faced similar review challenges? What worked for you? #SustainabilityReporting #ESG #InternalCoordination #ProjectManagement #ReportingDelays #BRSR #SustainabilityStrategy #ESGConsulting #CrossFunctionalTeams

While most developers are stuck in 14-month entitlement nightmares, top performers in Texas are getting approvals in 4-7 months using these 8 TACTICAL strategies: 1️⃣ Pre-Application Staff Alignment. * Meet with planning staff BEFORE submitting anything formal. * 73% of delayed projects skipped this critical step. * One can save 5 months by addressing staff concerns early. * Pro tip: Bring conceptual plans, not finished drawings, to these meetings. 2️⃣ Political Mapping Strategy. * Identify all decision makers and their key concerns/priorities. * Create a stakeholder map with voting history and hot-button issues. * Fast-tracked projects had commissioner-specific presentations. 3️⃣ Community Engagement Front-Loading. * Host neighborhood meetings BEFORE opposition forms. * Delayed projects faced organized community resistance. * Smart developers secure community support letters before the first hearing. 4️⃣ Parallel Processing Approach. * Run engineering and platting simultaneously with zoning. * Most developers wait for zoning approval before starting engineering. * Yes, there's risk if zoning fails, but the time savings is worth it. 5️⃣ Staff Report Influence Strategy. * Most of commission votes follow staff recommendations. * Top performers provide draft language for staff reports. * Secure favorable conditions by drafting specific language for staff. 6️⃣ Technical Studies Front-Loading. * Complete traffic, drainage, and environmental studies before first submission. * Delays come from study-related requests. * This approach costs more upfront but saves months on the back end. 7️⃣ Conditional Approval Targeting. * Identify non-critical conditions you can accept post-approval. * Focus commission attention on approval with conditions, not denial. * One developer in Montgomery County saved 3 months by accepting 12 conditions. 8️⃣ Expedited Review Fee Leverage. * Municipalities offer faster reviews for additional fees. * These fees ($5K-$15K) are nothing compared to carrying costs. * One project saved $127K in carrying costs by paying $8K in expedited fees. The entitlement game isn't about patience. It's about strategy and execution. __ Tu Amigo, David Cabrera P.S. Which of these strategies have you tried or think of trying out?

💡 How FDA Special Designations Accelerate Drug Approvals 🔆 Exhibit 1: Benefits and timing of FDA special designations in drug development Exhibit 2: Impact of special designations of key parameters Ever wonder how groundbreaking therapies reach patients faster? FDA special designations are not just regulatory steps—they're powerful accelerators. These aren’t just regulatory checkboxes—they’re powerful tools that speed up access to life-saving drugs for patients facing severe conditions. From Orphan Designation to Breakthrough Therapy, each designation plays a unique role in accelerating innovation while ensuring safety. While these designations expedite critical discussions and streamline the review process, they also come with challenges such as the need for rigorous post-approval studies to confirm long-term efficacy and safety. Despite these hurdles, some drugs still encounter approval setbacks. Let’s break down how these designations can expedite drug development process: ☑ Orphan Designation: Benefits drug development for rare diseases with fewer than 200,000 patients in the U.S., providing financial incentives like tax credits, R&D grants, and market exclusivity. ☑ Fast Track: Enables frequent communication with the FDA for drugs addressing serious conditions with unmet medical needs, facilitating a quicker issue resolution process and a rolling review system. ☑ Accelerated Approval: Allows drugs to be approved based on surrogate endpoints, benefiting patients by providing earlier access to treatments for serious conditions with no existing therapies. ☑ Priority Review: Shortens the FDA's review time for drugs offering significant advancements in treatment, diagnosis, or prevention of serious conditions. ☑ Breakthrough Therapy: Offers intensive FDA guidance and a streamlined review process for drugs showing substantial improvement over existing treatments for serious conditions. This designation offers a host of benefits, including intensive guidance from the FDA, a collaborative development approach, and rolling review The FDA's special designations play a vital role in revolutionizing the drug approval landscape, balancing innovation with oversight to accelerate critical treatments' availability while ensuring patient safety.

The FDA just launched AI to review your submissions. Weeks of waiting? Now it's done in hours. It's called Elsa and it's already live inside the FDA, transforming how your submissions get reviewed. Not tomorrow. Not next quarter. Today. Here's what this means for your next submission: ✅ Your reviews just got faster Elsa processes mountains of data in minutes. Product labeling that took days? Hours now. No more waiting weeks for initial feedback. ✅ Consistency is now the standard All FDA reviewers now use the same AI-powered logic. Same framework. Same language. Same approach. Your evaluation no longer depends on who reviews it. ✅ Your data stays secure Everything remains within the FDA's internal infrastructure. No external servers. No third-party access. Your proprietary information is safer than ever. ✅ Human expertise gets amplified Elsa generates summaries and drafts documentation. FDA reviewers still make all final decisions. They just work with better intelligence, delivered faster. For MedTech companies, this changes everything: ✓ Predictable review timelines ✓ Clearer submission requirements ✓ Faster go-to-market for life-saving devices ✓ More time for innovation, less for paperwork The smartest MedTech companies see what's happening. They're already restructuring submissions to align with AI-powered review processes. They're implementing their own AI tools to match FDA's new speed. Because here's what they understand: If the FDA trusts AI to accelerate reviews, why are you still doing compliance manually? Those that don't? They'll watch competitors get to market while they're still filling out spreadsheets. The future of MedTech compliance isn't coming. It's here. And the FDA just proved it. ♻️ Find this valuable? Repost for your network. 💡 Follow Bastian Krapinger-Ruether for actionable tips on MedTech compliance and QM. Tired of wasting time on repetitive compliance tasks? DM me to see how AI can automate 70% of your processes, so you can focus on what really matters.